DeGregorio Scientific Advisory Board


Help Us Turn Fact Into Fiction ™

Dr. Manish Shah – Scientific Advisory Board Chair

manish_shah_front_boxDr. Manish Shah is honored to serve as the Chair of the Scientific Advisory Committee for the DeGregorio Family Foundation for Gastric and Esophageal Cancers. He graduated from Johns Hopkins University in 1991 with a Bachelor’s of Science degree in Biomedical Engineering, and from Harvard Medical School/MIT Health Sciences and Technology program in 1996, graduating magna cum laude, with a MedicalDoctorate degree. He completed his Internal Medicine Residency training at Duke University Medical Center in 1999, and his Medical Oncology Fellowship at Memorial Sloan-Kettering Cancer Center in 2001, also serving as Chief Oncology Fellow. He is the recipient of several awards including the American Society of Clinical Oncology Young Investigator and Career Development Awards. He is currently the Director of Gastrointestinal Oncology within the Division of Hematology and Medical Oncology and the Center for Advanced Digestive Care at Weill Cornell Medical College / New York-Presbyterian Hospital. Dr. Shah is a national and international thought leader in drug development and the treatment of gastrointestinal malignancies. He is a distinguished peer-review funded investigator and has led several Phase I, II and III clinical trials in patients with advanced gastric cancer. Dr. Shah is also the Director of the Gastrointestinal Oncology Research Laboratory at Weill Cornell Medical College. His areas of translational research interests are in improving ourunderstanding of cancers of the upper GI tract as well as hereditary gastrointestinal malignancies. He is interested in power of genomic evaluations of malignancy and how the environment and personal risks can impact the genetic causes of malignancy. He is a peer-reviewer for NIH and NCI research funding, and a reviewer for several high impact journals including the Journal of the American Medical Association, Journal of Clinical Oncology, Annals of Surgery, Annals of Surgical Oncology, Clinical Cancer Research and Gastroenterology. Dr. Shah is also the Editor for The Management of Complex Cases in Gastrointestinal Oncology Case Series for the Journal Of Gastrointestinal Oncology and the Series Editor for the Dx/RX: Oncology Series published by Jones and Bartlett Publishers. He has authored several books including Dx/Rx: Upper Gastrointestinal Malignancies: Cancers of the Stomach and Esophagus, as well as 100 Questions and Answers about Stomach Cancer. He is a member of the American Society of Clinical Oncology (serving as a Cancer Education Committee Member), American Association of Cancer Research, and the American Gastroenterology Association.

Dr. Parry Guilford – Scientific Advisory Board member

front_page_vid_guilfordAssoc. Prof. Parry Guilford is a Principal Investigator in the Cancer Genetics Laboratory, University of Otago, Dunedin, New Zealand, and the Research Director of Pacific Edge Biotechnology Ltd. He completed his MSc at Otago in 1983, and his PhD at Cambridge University in 1989. His research interests include the genetics of inherited cancers, in particular stomach cancer, and the application of genetics to the diagnosis and management of cancer.

Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, Dwerryhouse S, Caldas C; International Gastric Cancer Linkage Consortium. J Med Genet. 2010 Jul;47(7):436-44. doi: 10.1136/jmg.2009.074237. Erratum in: J Med Genet. 2011 Mar;48(3):216. Van Krieken, Nicola [corrected to Van Grieken, Nicola C].

Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Guilford P, Humar B, Blair V.

Hereditary diffuse gastric cancer: a manifestation of lost cell polarity. Humar B, Guilford P. Cancer Sci. 2009 Jul;100(7):1151-7. doi: 10.1111/j.1349-7006.2009.01163.x. Epub 2009 Apr 21. Review.

E-cadherin deficiency initiates gastric signet-ring cell carcinoma in mice and man. Humar B, Blair V, Charlton A, More H, Martin I, Guilford P. Cancer Res. 2009 Mar 1;69(5):2050-6. doi: 10.1158/0008-5472.CAN-08-2457. Epub 2009 Feb 17.

A novel diffuse gastric cancer susceptibility variant in E-cadherin (CDH1) intron 2: a case control study in an Italian population. Nasri S, More H, Graziano F, Ruzzo A, Wilson E, Dunbier A, McKinney C, Merriman T, Guilford P, Magnani M, Humar B. BMC Cancer. 2008 May 15;8:138. doi: 10.1186/1471-2407-8-138.

Hereditary diffuse gastric cancer and lost cell polarity: a short path to cancer. Humar B, Guilford P. Future Oncol. 2008 Apr;4(2):229-39. doi: 10.2217/14796694.4.2.229. Review.

 Expression of Krüppel-like factor 5 in human gastric carcinomas. Kwak MK, Lee HJ, Hur K, Park do J, Lee HS, Kim WH, Lee KU, Choe KJ, Guilford P, Yang HK. J Cancer Res Clin Oncol. 2008 Feb;134(2):163-7. Epub 2007 Jul 11.

Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Humar B, Fukuzawa R, Blair V, Dunbier A, More H, Charlton A, Yang HK, Kim WH, Reeve AE, Martin I, Guilford P. Cancer Res. 2007 Mar 15;67(6):2480-9.

A short guide to hereditary diffuse gastric cancer. Guilford P, Blair V, More H, Humar B. Hered Cancer Clin Pract. 2007 Dec 15;5(4):183-94. doi: 10.1186/1897-4287-5-4-183.

Hereditary diffuse gastric cancer: diagnosis and management. Blair V, Martin I, Shaw D, Winship I, Kerr D, Arnold J, Harawira P, McLeod M, Parry S, Charlton A, Findlay M, Cox B, Humar B, More H, Guilford P. Clin Gastroenterol Hepatol. 2006 Mar;4(3):262-75. Review.

Prognostic analysis of E-cadherin gene promoter hypermethylation in patients with surgically resected, node-positive, diffuse gastric cancer. Graziano F, Arduini F, Ruzzo A, Bearzi I, Humar B, More H, Silva R, Muretto P, Guilford P, Testa E, Mari D, Magnani M, Cascinu S. Clin Cancer Res. 2004 Apr 15;10(8):2784-9.

Association of CDH1 haplotypes with susceptibility to sporadic diffuse gastric cancer. Humar B, Graziano F, Cascinu S, Catalano V, Ruzzo AM, Magnani M, Toro T, Burchill T, Futschik ME, Merriman T, Guilford P. Oncogene. 2002 Nov 21;21(53):8192-5.

Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. Humar B, Toro T, Graziano F, Müller H, Dobbie Z, Kwang-Yang H, Eng C, Hampel H, Gilbert D, Winship I, Parry S, Ward R, Findlay M, Christian A, Tucker M, Tucker K, Merriman T, Guilford P. Hum Mutat. 2002 May;19(5):518-25.

Henry T. Lynch, MD – Scientific Advisory Board member

front_page_henry_lynchHenry T. Lynch, MD, was born in Lawrence, Massachusetts, on January 4, 1928, and grew up in New York. Although underage, he enlisted in the United States Navy in March of 1944, and served in the European and South Pacific theaters. He received his bachelor’s degree from the University of Oklahoma, a master’s degree in clinical psychology from Denver University, and was nearing completion of a Ph.D. in human genetics when he entered medical school at the University of Texas Medical Branch in Galveston, from which he received his MD degree in 1960. He completed several post-degree medical training programs and was on the faculty of the University of Texas M.D. Anderson Cancer Center in Houston before coming to Creighton University School of Medicine in Omaha, Nebraska, in 1967. Since that time, he has been chairman of Preventative Medicine and Public Health at Creighton, advancing to full professor in 1972. During the 1960’s, when cancer was considered an almost solely environmentally-caused disease, Dr. Lynch demonstrated Mendelian inheritance patterns for a previously unrecognized form of colon cancer(hereditary nonpolyposis colorectal cancer, now known as Lynch syndrome), and for the hereditary breast-ovarian cancer syndrome, which he subsequently helped link to the BRCA1 and BRCA2 genes. In addition, he provided some of the first findings of the hereditary malignant melanoma and of familial aspects of prostate and pancreatic cancer. The purpose of this work has been to enable physicians to more quickly and accurately identify high-risk patients, leading to earlier and more effective surveillance, management, and treatment.
Dr. Lynch’s contributions to cancer research have been recognized by many awards from such groups as the American Cancer Society, Bristol-Myers Squibb, the American Association for Cancer Research, the Susan G. Komen Breast Cancer Foundation, and the American Society of Clinical Oncology.

Barrett’s esophagus in the patients with familial adenomatous polyposis. Gatalica Z, Chen M, Snyder C, Mittal S, Lynch HT. Fam Cancer. 2014 Jun;13(2):213-7. doi: 10.1007/s10689-013-9638-7.

The identification and management of hereditary diffuse gastric cancer in a large Jordanian family. Lynch HT, Aldoss I, Lynch JF. Fam Cancer. 2011 Dec;10(4):667-72. doi: 10.1007/s10689-011-9463-9.

Prevalence of Barrett esophagus in first-degree relatives of patients with esophageal adenocarcinoma. Juhasz A, Mittal SK, Lee TH, Deng C, Chak A, Lynch HT. J Clin Gastroenterol. 2011 Nov-Dec;45(10):867-71. doi: 10.1097/MCG.0b013e31821f44a8.

Hereditary diffuse gastric cancer: lifesaving total gastrectomy for CDH1 mutation carriers. Lynch HT, Lynch JF. J Med Genet. 2010 Jul;47(7):433-5. doi: 10.1136/jmg.2010.078170. No abstract available.

Hereditary diffuse gastric cancer: diagnosis, genetic counseling, and prophylactic total gastrectomy. Lynch HT, Kaurah P, Wirtzfeld D, Rubinstein WS, Weissman S, Lynch JF, Grady W, Wiyrick S, Senz J, Huntsman DG. Cancer. 2008 Jun 15;112(12):2655-63. doi: 10.1002/cncr.23501.

Gastric cancer: new genetic developments. Lynch HT, Grady W, Suriano G, Huntsman D. J Surg Oncol. 2005 Jun 1;90(3):114-33; discussion 133.

Keith T. Wilson, MD – Scientific Advisory Board member

wilson-keith

Dr. Keith Wilson received his medical degree from Harvard Medical School and his undergraduate degree from Cornell University.  He is currently a Professor of Medicine at Vanderbilt University School of Medicine, as well as Professor of Pathology, Microbiology and Immunology, Professor of Cancer Biology and a Thomas F. Frist St. Chair in Medicine.  He is also a Director of Research and Fellowship Training Program, Division of Gastroenterology, Hepatology, and Nutrition Research

Dr. Wilson’s work is focused on gastrointestinal mucosal inflammation and carcinogenesis.  His studies include the host immune response to the gastric pathogen Helicobacter pylori that causes peptic ulcer disease and gastric cancer. This includes the innate immune response in macrophages and the identification of ways that this response is ineffective. Additionally, his work has also revealed mechanisms whereby epithelial responses are inappropriate, leading to risk for cancer development and the study novel mechanisms for inflammation and cellular/DNA damage, which leads to increased cancer risk.

Click here  to read more about Dr. Wilson’s research and a complete list of his published reports moe-info

Varga MG, Piazuelo MB, Romero-Gallo J, Delgado AG, Suarez G, Whitaker ME, Krishna US, Patel RV, Skaar EP, Wilson KT, Algood HM, Peek RM.TLR9 Activation Suppresses Inflammation in Response to Helicobacter pylori InfectionAm. J. Physiol. Gastrointest. Liver Physiol [print-electronic]. 2016 Oct 10/6/2016; ajpgi.00175.2016. PMID: 27758771, PII: ajpgi.00175.2016, DOI: 10.1152/ajpgi.00175.2016, ISSN: 1522-1547.

Singh K, Al-Greene NT, Verriere TG, Coburn LA, Asim M, Barry DP, Allaman MM, Hardbower DM, Delgado AG, Piazuelo MB, Vallance BA, Gobert AP,Wilson KTThe L-Arginine Transporter Solute Carrier Family 7 Member 2 Mediates the Immunopathogenesis of Attaching and Effacing BacteriaPLoS Pathog. 2016 Oct; 12(10): e1005984. PMID: 27783672, PII: PPATHOGENS-D-16-01126, DOI: 10.1371/journal.ppat.1005984, ISSN: 1553-7374.

Gobert AP, Wilson KTPolyamine- and NADPH-dependent generation of ROS during Helicobacter pylori infection: A blessing in disguiseFree Radic. Biol. Med [print-electronic]. 2016 Sep 9/25/2016; PMID: 27682363, PII: S0891-5849(16)30435-X, DOI: 10.1016/j.freeradbiomed.2016.09.024, ISSN: 1873-4596.

Hardbower DM, Singh K, Asim M, Verriere TG, Olivares-Villagómez D, Barry DP, Allaman MM, Washington MK, Peek RM, Piazuelo MB, Wilson KT.EGFR regulates macrophage activation and function in bacterial infectionJ. Clin. Invest [print-electronic]. 2016 Sep 9/1/2016; 126(9): 3296-312. PMID: 27482886, PMCID: PMC5004944, PII: 83585, DOI: 10.1172/JCI83585, ISSN: 1558-8238.

 

Dr. David Kelsen – Scientific Advisory Board member

front_page_david_kelsenDr. Kelsen is incumbent of the Edward S Gordon Chair in Medical Oncology and Chief of The Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, and Professor of Medicine at Weill Medical College of Cornell University, New York. Dr. Kelsen’s research focuses on developmental therapeutics and multimodality therapy of gastrointestinal malignancies. He has served on several national committees, including the Oncologic Drugs Advisory Committee of the Food and Drug Administration, and is past Chairman of Research Council at MSKCC.
He has received peer reviewed grant support for his research from the National Institutes of Health, the National Cancer Institute, and the American Cancer Society, and is currently the Principal Investigator of an NCI 01 for the Early Therapeutics with Phase 2 Emphasis.

Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.

Park do J, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, Ilson DH, Goodman KA, Tang LH, Strong VE, Coit DG, Yoon SS.

Ann Surg Oncol. 2014 Apr;21(4):1130-7. doi: 10.1245/s10434-013-3429-0. Epub 2013 Dec 27.

Phase II Trial of Cetuximab Plus Cisplatin and Irinotecan in Patients With Cisplatin and Irinotecan-refractory Metastatic Esophagogastric Cancer.

Janjigian YY, Ku GY, Campbell JC, Shah MA, Capanu M, Kelsen DP, Ilson DH.

Am J Clin Oncol. 2012 Dec 1. [Epub ahead of print]

A case of advanced gastric cancer.

Ang C, Janjigian YY, Shamseddine A, Tawil A, Lowery MA, Intlekofer A, Faraj W, Al-Olayan A, Tang L, O’Reilly EM, Geara F, Al-Kutoubi A, Kelsen DP, Abou-Alfa GK.

Gastrointest Cancer Res. 2012 Mar;5(2):59-63. No abstract available.

A prospective evaluation of the utility of 2-deoxy-2-[(18) F]fluoro-D-glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer.

Smyth E, Schöder H, Strong VE, Capanu M, Kelsen DP, Coit DG, Shah MA.

Cancer. 2012 Nov 15;118(22):5481-8. doi: 10.1002/cncr.27550. Epub 2012 May 1.


Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer.

Ilson DH, Minsky BD, Ku GY, Rusch V, Rizk N, Shah M, Kelsen DP, Capanu M, Tang L, Campbell J, Bains M.

Cancer. 2012 Jun 1;118(11):2820-7. doi: 10.1002/cncr.26591. Epub 2011 Oct 11.

Molecular classification of gastric cancer: a new paradigm.

Shah MA, Khanin R, Tang L, Janjigian YY, Klimstra DS, Gerdes H, Kelsen DP.

Clin Cancer Res. 2011 May 1;17(9):2693-701. doi: 10.1158/1078-0432.CCR-10-2203. Epub 2011 Mar 23

A phase 2 trial of erlotinib in patients with previously treated squamous cell and adenocarcinoma of the esophagus.

Ilson DH, Kelsen D, Shah M, Schwartz G, Levine DA, Boyd J, Capanu M, Miron B, Klimstra D.

Cancer. 2011 Apr 1;117(7):1409-14. doi: 10.1002/cncr.25602. Epub 2010 Nov 8.

MET expression and amplification in patients with localized gastric cancer.

Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC, Shah MA.

Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1021-7. doi: 10.1158/1055-9965.EPI-10-1080. Epub 2011 Mar 10.

Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.

Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP.

J Clin Oncol. 2011 Mar 1;29(7):868-74. doi: 10.1200/JCO.2010.32.0770. Epub 2010 Dec 28.

A multicenter, phase II study of bortezomib (PS-341) in patients with unresectable or metastatic gastric and gastroesophageal junction adenocarcinoma.

Shah MA, Power DG, Kindler HL, Holen KD, Kemeny MM, Ilson DH, Tang L, Capanu M, Wright JJ, Kelsen DP.

Invest New Drugs. 2011 Dec;29(6):1475-81. doi: 10.1007/s10637-010-9474-7. Epub 2010 Jun 25.

Gastrointestinal cancer educational case series: the history and management of complex cases in gi oncology. A 72 year-old man with metastatic gastric cancer.

Smyth E, Abou-Alfa GK, Lowery M, Shamseddine A, Al-Olayan A, Naghy M, Power D, Saliba T, Kelsen D, Shah MA.

J Gastrointest Cancer. 2011 Mar;42(1):46-9. doi: 10.1007/s12029-010-9170-z.

Gastric cancer: a primer on the epidemiology and biology of the disease and an overview of the medical management of advanced disease.

Shah MA, Kelsen DP.

J Natl Compr Canc Netw. 2010 Apr;8(4):437-47. Review.

Advanced gastric cancer–slow but steady progress.

Power DG, Kelsen DP, Shah MA.

Cancer Treat Rev. 2010 Aug;36(5):384-92. doi: 10.1016/j.ctrv.2010.01.005. Epub 2010 Feb 21. Review.

Perineural invasion after preoperative chemotherapy predicts poor survival in patients with locally advanced gastric cancer: gene expression analysis with pathologic validation.

Jhawer M, Coit D, Brennan M, Qin LX, Gonen M, Klimstra D, Tang L, Kelsen DP, Shah MA.

Am J Clin Oncol. 2009 Aug;32(4):356-62. doi: 10.1097/COC.0b013e31818c08e8.

Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114).

Schwartz GK, Winter K, Minsky BD, Crane C, Thomson PJ, Anne P, Gross H, Willett C, Kelsen D.

J Clin Oncol. 2009 Apr 20;27(12):1956-62. doi: 10.1200/JCO.2008.20.3745. Epub 2009 Mar 9.

Endoscopic ultrasound can improve the selection for laparoscopy in patients with localized gastric cancer.

Power DG, Schattner MA, Gerdes H, Brenner B, Markowitz AJ, Capanu M, Coit DG, Brennan M, Kelsen DP, Shah MA.

J Am Coll Surg. 2009 Feb;208(2):173-8. doi: 10.1016/j.jamcollsurg.2008.10.022. Epub 2008 Dec 18.

Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113.

Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D, Willett CG.

J Clin Oncol. 2008 Oct 1;26(28):4551-6. doi: 10.1200/JCO.2008.16.6918. Epub 2008 Jun 23.

S-1 adjuvant chemotherapy for advanced gastric cancer.

Kelsen D.

Nat Clin Pract Oncol. 2008 Jul;5(7):370-1. doi: 10.1038/ncponc1152. Epub 2008 Jun 3. No abstract available.

Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer.

Ku GY, Ilson DH, Schwartz LH, Capanu M, O’Reilly E, Shah MA, Kelsen DP, Schwartz GK.

Cancer Chemother Pharmacol. 2008 Oct;62(5):875-80. doi: 10.1007/s00280-008-0677-y. Epub 2008 Feb 13.

Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer.

Kelsen DP, Winter KA, Gunderson LL, Mortimer J, Estes NC, Haller DG, Ajani JA, Kocha W, Minsky BD, Roth JA, Willett CG; Radiation Therapy Oncology Group; USA Intergroup.

J Clin Oncol. 2007 Aug 20;25(24):3719-25.

Incorporation of biologic therapies in the management of gastroesophageal cancers.

Jhawer M, Kelsen D, Shah M.

Gastrointest Cancer Res. 2007 Mar;1(2 Suppl):S22-9.

Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

Shah MA, Ramanathan RK, Ilson DH, Levnor A, D’Adamo D, O’Reilly E, Tse A, Trocola R, Schwartz L, Capanu M, Schwartz GK, Kelsen DP.

J Clin Oncol. 2006 Nov 20;24(33):5201-6.

Multimodality therapy of local regional esophageal cancer.

Kelsen DP.

Semin Oncol. 2005 Dec;32(6 Suppl 9):S6-10. Review.

Targeted therapies for esophageal cancer.

Tew WP, Kelsen DP, Ilson DH.

Oncologist. 2005 Sep;10(8):590-601. Review.


Thromboembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy.

Shah MA, Ilson D, Kelsen DP.

J Clin Oncol. 2005 Apr 10;23(11):2574-6. Epub 2005 Mar 28. No abstract available.

Pelvic CT in patients with esophageal cancer.

Gollub MJ, Lefkowitz R, Moskowitz CS, Ilson D, Kelsen D, Felderman H.

AJR Am J Roentgenol. 2005 Feb;184(2):487-90.

Combined modality therapy in esophageal cancer: the Memorial experience.

Anderson SE, Minsky BD, Bains M, Kelsen DP, Ilson DH.

Semin Surg Oncol. 2003;21(4):228-32.

Phase II trial of 96-hour paclitaxel in previously treated patients with advanced esophageal cancer.

Anderson SE, O’Reilly EM, Kelsen DP, Ilson DH.

Cancer Invest. 2003;21(4):512-6.

Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.

Ilson DH, Bains M, Kelsen DP, O’Reilly E, Karpeh M, Coit D, Rusch V, Gonen M, Wilson K, Minsky BD.

J Clin Oncol. 2003 Aug 1;21(15):2926-32.


A phase II trial of preoperative combined-modality therapy for localized esophageal carcinoma: initial results.

Bains MS, Stojadinovic A, Minsky B, Rusch V, Turnbull A, Korst R, Ginsberg R, Kelsen DP, Ilson DH.

J Thorac Cardiovasc Surg. 2002 Aug;124(2):270-7.

Irinotecan, cisplatin, and radiation in esophageal cancer.

Ilson DH, Minsky B, Kelsen D.

Oncology (Williston Park). 2002 May;16(5 Suppl 5):11-5. Review.

INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy.

Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP.

J Clin Oncol. 2002 Mar 1;20(5):1167-74.

 

Lee M. Ellis, MD – Scientific Advisory Board member

front_page_lee_ellisProfessor of Surgical Oncology and Cancer Biology The William C. Liedtke, Jr., Chair in Cancer Research Lee M. Ellis, MD, graduated from the University of Virginia School of Medicine in 1983, and completed his residency in surgery at the University of Florida in 1990. Dr. Ellis went on to complete a surgical oncology fellowship at the M. D. Anderson Cancer Center (MDACC), where he has been on the faculty since 1993. He has a dual appointment as a Professor in the departments of Surgical Oncology and Cancer Biology. Dr. Ellis has a clinical practice in Surgical Oncology, focused on patients with colorectal cancer and liver metastases. Academically, Dr. Ellis has established a reputation for expertise in the area of angiogenesis and growth factor receptors in gastrointestinal malignancies and is funded by several grants for research in this area. He has served on numerous NIH study sections and is a consultant to the National Cancer Institute, where he currently serves on the NCI GI Cancers Steering Committee. In 2000, Dr. Ellis was awarded the Faculty Scholar Award from the MDACC, and he was also the inaugural recipient of a grant from the George and Barbara Bush Endowment for Innovative Cancer Research. In 2007, he was awarded the William C. Liedtke, Jr., Chair in Cancer Research. Dr. Ellis serves on 8 editorial boards, including the Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research (Senior Editor). Dr. Ellis has also authored over 200 peer-reviewed publications, 90 invited reviews and editorials, three books, and 30 book chapters. In addition, he has published important editorials in journals such as the NEJM, Nature, Cell, Cancer Cell, Nature Medicine, JNCI, JCO, and The Lancet. Dr. Ellis has been a plenary discussant at ASCO twice in the last 5 yrs. He is co-chair of the largest clinical angiogenesis meeting in the world held annually in February.
Dr. Ellis serves in a leadership role in the major cancer societies such as the American Society for Clinical Oncology, American Association for Cancer Research, Keystone Scientific Symposia, and the Society for Surgical Oncology, where he has served on numerous committees. Dr. Ellis currently serves on the ECOG DMB. He was chair of the 2007 GI Cancers Symposium and was co-chair of the 2009 AACR annual meeting and is currently co-chair of the 2011 AACR Annual Meeting Program and Education Committees. He is on the Education Committee for the 2011 ASCO Meeting where he heads the Tumor Biology track. Dr. Ellis chaired a Keystone Symposium on Angiogenesis in January 2009. In June 2008, he was appointed Chair, Ad Interim, Department of Cancer Biology at MDACC.
 

Cancer: The nuances of therapy.

Ellis LM, Reardon DA.

Nature. 2009 Mar 19;458(7236):290-2. doi: 10.1038/458290a. No abstract available. 

Drug development: Raise standards for preclinical cancer research.

Begley CG, Ellis LM.

Nature. 2012 Mar 28;483(7391):531-3


Interleukin-1beta stimulates IL-8 expression through MAP kinase and ROS signaling in human gastric carcinoma cells.

Hwang YS, Jeong M, Park JS, Kim MH, Lee DB, Shin BA, Mukaida N, Ellis LM, Kim HR, Ahn BW, Jung YD.

Oncogene. 2004 Aug 26;23(39):6603-11.

Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation.

Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A, Bucana CD, Semenza GL, Ellis LM.

J Natl Cancer Inst. 2004 Jun 16;96(12):946-56.

Generation of monoclonal antibody MS17-57 targeting secreted alkaline phosphatase ectopically expressed on the surface of gastrointestinal cancer cells.

Li M, Gao J, Feng R, Wang Y, Chen X, Sun J, Zhang D, Zhu Z, Ellis LM, Lu M, Lee JE, Feng Z, Liu B. PLoS One. 2013 Oct 15;8(10):e77398. 

Regulation of vascular endothelial growth factor expression in human gastric cancer cells by interleukin-1beta.

Kawaguchi M, Akagi M, Gray MJ, Liu W, Fan F, Ellis LM.

Surgery. 2004 Sep;136(3):686-92.

ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer.

McCarty MF, Takeda A, Stoeltzing O, Liu W, Fan F, Reinmuth N, Akagi M, Bucana C, Mansfield PF, Ryan A, Ellis LM.

Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells.

Akagi M, Kawaguchi M, Liu W, McCarty MF, Takeda A, Fan F, Stoeltzing O, Parikh AA, Jung YD, Bucana CD, Mansfield PF, Hicklin DJ, Ellis LM.

Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model.

Jung YD, Mansfield PF, Akagi M, Takeda A, Liu W, Bucana CD, Hicklin DJ, Ellis LM.

Eur J Cancer. 2002 May;38(8):1133-40.

Significance of platelet-derived endothelial cell growth factor in the angiogenesis of human gastric cancer.

Takahashi Y, Bucana CD, Akagi Y, Liu W, Cleary KR, Mai M, Ellis LM.

Clin Cancer Res. 1998 Feb;4(2):429-34.

Significance of vessel count and vascular endothelial growth factor and its receptor (KDR) in intestinal-type gastric cancer.

Takahashi Y, Cleary KR, Mai M, Kitadai Y, Bucana CD, Ellis LM.

Clin Cancer Res. 1996 Oct;2(10):1679-84.

Serum levels of transforming growth factor alpha in gastrointestinal cancer patients.

Moskal TL, Huang S, Ellis LM, Fritsche HA Jr, Chakrabarty S.

Cancer Epidemiol Biomarkers Prev. 1995 Mar;4(2):127-31.

 

Dr. Timothy C. Wang – Scientific Advisory Board member

front_page_timothy_wangDr. Timothy C. Wang is the Silberberg Professor of Medicine and Chair of the Division of Gastroenterology. He received his MD from Columbia University, followed by clinical training at Washington University and Harvard/MGH. His main interest is in murine models of gastric cancer, and the role of stem cells in inflammation-associated cancer. Dr. Wang’s laboratory reported that gastric cancer in murine models can originate from bone marrow-derived stem cells. A separate project has identified markers for human gastric cancer stem cells. As the leader of the Columbia University Tumor Microenvironment Network, he has investigated the importance of the stem cell niche in governing stem cell differentiation, and how this niche is altered in chronic inflammatory states that predispose to cancer. He is currently investigating the role of both fibroblasts and myeloid cells in carcinogenesis.
Dr. Wang is a recipient of the AGA Funderberg Gastric Cancer Award and is the Editor of the first textbook on gastric cancer, “The Biology of Gastric Cancer” (Springer 2008). He is the Chair of the GCMB NIH study section, Chair of the AGA Future Trends Committee, Associate Editor for Gastroenterology, Editor in Chief of Therapeutic Advances in Gastroenterology. He is the author of more than 160 peer-reviewed publications.
 

Fluorescent nanoparticle imaging allows noninvasive evaluation of immune cell modulation in esophageal dysplasia.

Habibollahi P, Waldron T, Heidari P, Sung Cho H, Alcantara D, Josephson L, Wang TC, Rustgi AK, Mahmood U.

Mol Imaging. 2014 May 1;13(3):1-11.

Barrett’s Esophagus Translational Research Network (BETRNet): The Pivotal Role of Multi-institutional Collaboration in Esophageal Adenocarcinoma Research.

Abrams JA, Appelman HD, Beer DG, Berry LD, Chak A, Falk GW, Fitzgerald RC, Ginsberg GG, Grady WM, Joshi BP, Lynch JP, Markowitz S, Richmond ES, Rustgi AK, Seibel EJ, Shaheen NJ, Shyr Y, Umar A, Wang KK, Wang TC, Wang TD, Yassin R.

Gastroenterology. 2014 Jun;146(7):1586-90. doi: 10.1053/j.gastro.2014.04.014. Epub 2014 Apr 21. 

Optical imaging of periostin enables early endoscopic detection and characterization of esophageal cancer in mice.

Wong GS, Habibollahi P, Heidari P, Lee JS, Klein-Szanto AJ, Waldron TJ, Gimotty P, Nakagawa H, Taylor PR, Wang TC, Mahmood U, Rustgi AK.

Gastroenterology. 2013 Feb;144(2):294-7. doi: 

Barrett esophagus: what a mouse model can teach us about human disease.

Quante M, Abrams JA, Lee Y, Wang TC.

Cell Cycle. 2012 Dec 1;11(23):4328-38. doi: 10.4161/cc.22485. Epub 2012 Oct 24. Review.

The unfolded protein response is activated in Helicobacter-induced gastric carcinogenesis in a non-cell autonomous manner.

Baird M, Woon Ang P, Clark I, Bishop D, Oshima M, Cook MC, Hemmings C, Takeishi S, Worthley D, Boussioutas A, Wang TC, Taupin D.

Lab Invest. 2013 Jan;93(1):112-22. doi: 10.1038/labinvest.2012.131. Epub 2012 Oct 29.

Folic acid increases global DNA methylation and reduces inflammation to prevent Helicobacter-associated gastric cancer in mice.

Gonda TA, Kim YI, Salas MC, Gamble MV, Shibata W, Muthupalani S, Sohn KJ, Abrams JA, Fox JG, Wang TC, Tycko B.

Gastroenterology. 2012 Apr;142(4):824-833.e7. doi: 10.1053/j.gastro.2011.12.058. Epub 2012 Jan 13.

Trefoil factor 2 requires Na/H exchanger 2 activity to enhance mouse gastric epithelial repair.

Xue L, Aihara E, Wang TC, Montrose MH.

J Biol Chem. 2011 Nov 4;286(44):38375-82. doi: 10.1074/jbc.M111.268219. Epub 2011 Sep 7.

PMID:21900251

Systemic activation of K-ras rapidly induces gastric hyperplasia and metaplasia in mice.

Matkar SS, Durham A, Brice A, Wang TC, Rustgi AK, Hua X.

Am J Cancer Res. 2011 Apr 1;1(4):432-445.

 17β-estradiol and tamoxifen prevent gastric cancer by modulating leukocyte recruitment and oncogenic pathways in Helicobacter pylori-infected INS-GAS male mice.

Sheh A, Ge Z, Parry NM, Muthupalani S, Rager JE, Raczynski AR, Mobley MW, McCabe AF, Fry RC, Wang TC, Fox JG.

Cancer Prev Res (Phila). 2011 Sep;4(9):1426-35. doi: 10.1158/1940-6207.CAPR-11-0219. Epub 2011 Jun 16.

K-ras mutation targeted to gastric tissue progenitor cells results in chronic inflammation, an altered microenvironment, and progression to intraepithelial neoplasia.

Okumura T, Ericksen RE, Takaishi S, Wang SS, Dubeykovskiy Z, Shibata W, Betz KS, Muthupalani S, Rogers AB, Fox JG, Rustgi AK, Wang TC.

Cancer Res. 2010 Nov 1;70(21):8435-45. doi: 10.1158/0008-5472.CAN-10-1506. Epub 2010 Oct 19.

Helicobacter pylori infection promotes methylation and silencing of trefoil factor 2, leading to gastric tumor development in mice and humans.

Peterson AJ, Menheniott TR, O’Connor L, Walduck AK, Fox JG, Kawakami K, Minamoto T, Ong EK, Wang TC, Judd LM, Giraud AS.

Gastroenterology. 2010 Dec;139(6):2005-17. doi: 10.1053/j.gastro.2010.08.043. Epub 2010 Aug 27.

Human Barrett’s adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant.

Hutchinson L, Stenstrom B, Chen D, Piperdi B, Levey S, Lyle S, Wang TC, Houghton J.

Stem Cells Dev. 2011 Jan;20(1):11-7. doi: 10.1089/scd.2010.0139. Epub 2010 Oct 12.

PMID:20677919

Spasmolytic polypeptide-expressing metaplasia and intestinal metaplasia: time for reevaluation of metaplasias and the origins of gastric cancer.

Goldenring JR, Nam KT, Wang TC, Mills JC, Wright NA.

Gastroenterology. 2010 Jun;138(7):2207-10, 2210.e1. doi: 10.1053/j.gastro.2010.04.023. Epub 2010 May 5. No abstract available

Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett’s esophagus.

Wang JS, Varro A, Lightdale CJ, Lertkowit N, Slack KN, Fingerhood ML, Tsai WY, Wang TC, Abrams JA.

Am J Gastroenterol. 2010 May;105(5):1039-45. doi: 10.1038/ajg.2009.629. Epub 2009 Nov 10.

Combination of sulindac and antimicrobial eradication of Helicobacter pylori prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.

Lee CW, Rickman B, Rogers AB, Muthupalani S, Takaishi S, Yang P, Wang TC, Fox JG.

Cancer Res. 2009 Oct 15;69(20):8166-74. doi: 10.1158/0008-5472.CAN-08-3856. Epub 2009 Oct 13.

Gastrin is an essential cofactor for helicobacter-associated gastric corpus carcinogenesis in C57BL/6 mice.

Takaishi S, Tu S, Dubeykovskaya ZA, Whary MT, Muthupalani S, Rickman BH, Rogers AB, Lertkowit N, Varro A, Fox JG, Wang TC.

Am J Pathol. 2009 Jul;175(1):365-75. doi: 10.2353/ajpath.2009.081165.

p53 inhibition of AP1-dependent TFF2 expression induces apoptosis and inhibits cell migration in gastric cancer cells.

Tu SP, Chi AL, Ai W, Takaishi S, Dubeykovskaya Z, Quante M, Fox JG, Wang TC.

Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G385-96. doi: 10.1152/ajpgi.90620.2008. Epub 2009 Jun 18.

Identification of gastric cancer stem cells using the cell surface marker CD44.

Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, Gordon SA, Shimada Y, Wang TC.

Stem Cells. 2009 May;27(5):1006-20. doi: 10.1002/stem.30.

Altered gastric chief cell lineage differentiation in histamine-deficient mice.

Nozaki K, Weis V, Wang TC, Falus A, Goldenring JR.

Am J Physiol Gastrointest Liver Physiol. 2009 Jun;296(6):G1211-20. doi: 10.1152/ajpgi.90643.2008. Epub 2009 Apr 9.

Identification of ezrin as a target of gastrin in immature mouse gastric parietal cells.

Pagliocca A, Hegyi P, Venglovecz V, Rackstraw SA, Khan Z, Burdyga G, Wang TC, Dimaline R, Varro A, Dockray GJ.

Exp Physiol. 2008 Nov;93(11):1174-89. doi: 10.1113/expphysiol.2008.042648. Epub 2008 Jun 20.

Gastric cancer stem cells.

Takaishi S, Okumura T, Wang TC.

J Clin Oncol. 2008 Jun 10;26(17):2876-82. doi: 10.1200/JCO.2007.15.2603. Review.

Helicobacter pylori eradication prevents progression of gastric cancer in hypergastrinemic INS-GAS mice.

Lee CW, Rickman B, Rogers AB, Ge Z, Wang TC, Fox JG.

Cancer Res. 2008 May 1;68(9):3540-8. doi: 10.1158/0008-5472.CAN-07-6786. Epub 2008 Apr 25.

Vitamin C supplementation does not protect L-gulono-gamma-lactone oxidase-deficient mice from Helicobacter pylori-induced gastritis and gastric premalignancy.

Lee CW, Wang XD, Chien KL, Ge Z, Rickman BH, Rogers AB, Varro A, Whary MT, Wang TC, Fox JG.

Int J Cancer. 2008 Mar 1;122(5):1068-76.

Protective role of 17 beta -estradiol against the development of Helicobacter pylori-induced gastric cancer in INS-GAS mice.

Ohtani M, García A, Rogers AB, Ge Z, Taylor NS, Xu S, Watanabe K, Marini RP, Whary MT, Wang TC, Fox JG.

Carcinogenesis. 2007 Dec;28(12):2597-604. Epub 2007 Aug 27.

Helicobacter and gastrin stimulate Reg1 expression in gastric epithelial cells through distinct promoter elements.

Steele IA, Dimaline R, Pritchard DM, Peek RM Jr, Wang TC, Dockray GJ, Varro A.

Am J Physiol Gastrointest Liver Physiol. 2007 Jul;293(1):G347-54. Epub 2007 Apr 26.


Swedish moist snuff accelerates gastric cancer development in Helicobacter pylori-infected wild-type and gastrin transgenic mice.

Stenström B, Zhao CM, Rogers AB, Nilsson HO, Sturegård E, Lundgren S, Fox JG, Wang TC, Wadström TM, Chen D.

Carcinogenesis. 2007 Sep;28(9):2041-6. Epub 2007 Mar 26.

Gene expression profiling in a mouse model of Helicobacter-induced gastric cancer.

Takaishi S, Wang TC.

Cancer Sci. 2007 Mar;98(3):284-93.

Inflammation, atrophy, and gastric cancer.

Fox JG, Wang TC.

J Clin Invest. 2007 Jan;117(1):60-9. Review.

Gastrin-induced apoptosis contributes to carcinogenesis in the stomach.

Cui G, Takaishi S, Ai W, Betz KS, Florholmen J, Koh TJ, Houghton J, Pritchard DM, Wang TC.

Lab Invest. 2006 Oct;86(10):1037-51. Epub 2006 Aug 7.

The role of matrix metalloproteinase-7 in redefining the gastric microenvironment in response to Helicobacter pylori.

McCaig C, Duval C, Hemers E, Steele I, Pritchard DM, Przemeck S, Dimaline R, Ahmed S, Bodger K, Kerrigan DD, Wang TC, Dockray GJ, Varro A.

Gastroenterology. 2006 May;130(6):1754-63. Epub 2006 Mar 6.

Synergistic inhibitory effects of gastrin and histamine receptor antagonists on Helicobacter-induced gastric cancer.

Takaishi S, Cui G, Frederick DM, Carlson JE, Houghton J, Varro A, Dockray GJ, Ge Z, Whary MT, Rogers AB, Fox JG, Wang TC.

Gastroenterology. 2005 Jun;128(7):1965-83.

Helicobacter felis eradication restores normal architecture and inhibits gastric cancer progression in C57BL/6 mice.

Cai X, Carlson J, Stoicov C, Li H, Wang TC, Houghton J.

Gastroenterology. 2005 Jun;128(7):1937-52.

Helicobacter pylori and gastric cancer: a new paradigm for inflammation-associated epithelial cancers.

Houghton J, Wang TC.

Gastroenterology. 2005 May;128(6):1567-78. Review.

PMID:15887152

Alterations in gastric mucosal lineages induced by acute oxyntic atrophy in wild-type and gastrin-deficient mice.

Nomura S, Yamaguchi H, Ogawa M, Wang TC, Lee JR, Goldenring JR.

Am J Physiol Gastrointest Liver Physiol. 2005 Feb;288(2):G362-75.

Helicobacter and gastric cancer disease mechanisms: host response and disease susceptibility.

Li H, Stoicov C, Cai X, Wang TC, Houghton J.

Curr Gastroenterol Rep. 2003 Dec;5(6):459-67. Review.

Expression of cytoplasmic TFF2 is a marker of tumor metastasis and negative prognostic factor in gastric cancer.

Dhar DK, Wang TC, Maruyama R, Udagawa J, Kubota H, Fuji T, Tachibana M, Ono T, Otani H, Nagasue N.

Lab Invest. 2003 Sep;83(9):1343-52.

Germ-line p53-targeted disruption inhibits helicobacter-induced premalignant lesions and invasive gastric carcinoma through down-regulation of Th1 proinflammatory responses.

Fox JG, Sheppard BJ, Dangler CA, Whary MT, Ihrig M, Wang TC.

Cancer Res. 2002 Feb 1;62(3):696-702.

Dr. Adam Bass – Scientific Advisory Board member

front_page_adam_bassDr. Adam Bass is an assistant professor of medicine at the Harvard Medical School and Dana-Farber Cancer Institute and also is an associate member of the Broad Institute. He completed clinical training in internal medicine at the Massachusetts General Hospital and medical oncology training at the Dana-Farber Cancer Institute. He subsequently pursued research training in cancer genomics and cancer biology at both the Dana-Farber Cancer Institute and Broad Institute. During that time he developed a research interest in studying the somatic-genomic alterations in gastrointestinal cancer using new emerging genomic technologies and also studying candidate genomic alterations in the laboratory using more traditional functional biology.
Since 2010, Dr. Bass been an independent investigator at the Dana-Farber Cancer Institute ,where his laboratory continues to pursue the understanding of the genomic alterations in gastrointestinal cancers, with a special interest in esophageal and gastric cancers. In addition, Dr. Bass is co‑chairing The Cancer Genome Atlas (TCGA) studies into gastric and esophageal cancer. Beyond genomic characterization, his laboratory continues to work to understand select oncogenes and tumor suppressors in these tumors and build off the elucidation of genomic alterations to identify new therapeutic vulnerabilities for patients with these diseases.
 

Bandla S, Peters JH, Ruff D, Chen SM, Li CY, Song K, Thoms K, Litle VR, Watson T, Chapurin N, Lada M, Pennathur A, Luketich JD, Peterson D, Dulak A, Lin L, Bass A, Beer DG, Godfrey TE, Zhou Z.

Ann Surg. 2014 Jul;260(1):72-80.

Gastrointestinal adenocarcinomas of the esophagus, stomach, and colon exhibit distinct patterns of genome instability and oncogenesis.

Dulak AM, Schumacher SE, van Lieshout J, Imamura Y, Fox C, Shim B, Ramos AH, Saksena G, Baca SC, Baselga J, Tabernero J, Barretina J, Enzinger PC, Corso G, Roviello F, Lin L, Bandla S, Luketich JD, Pennathur A, Meyerson M, Ogino S, Shivdasani RA, Beer DG, Godfrey TE, Beroukhim R, Bass AJ.

Cancer Res. 2012 Sep 1;72(17):4383-93. Epub 2012 Jul 2.

Optical Imaging with a Cathepsin B Activated Probe for the Enhanced Detection of Esophageal Adenocarcinoma by Dual Channel Fluorescent Upper GI Endoscopy.

Habibollahi P, Figueiredo JL, Heidari P, Dulak AM, Imamura Y, Bass AJ, Ogino S, Chan AT, Mahmood U.

Theranostics. 2012;2(2):227-34. doi: 10.7150/thno.4088. Epub 2012 Feb 16.

Activation of GATA binding protein 6 (GATA6) sustains oncogenic lineage-survival in esophageal adenocarcinoma.

Lin L, Bass AJ, Lockwood WW, Wang Z, Silvers AL, Thomas DG, Chang AC, Lin J, Orringer MB, Li W, Glover TW, Giordano TJ, Lam WL, Meyerson M, Beer DG.

Proc Natl Acad Sci U S A. 2012 Mar 13;109(11):4251-6. doi: 10.1073/pnas.1011989109. Epub 2012 Feb 28.

SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.

Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O’Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, Wagner P, Minna JD, Gazdar AF, Zhu CQ, Brose MS, Cecconello I, Jr UR, Marie SK, Dahl O, Shivdasani RA, Tsao MS, Rubin MA, Wong KK, Regev A, Hahn WC, Beer DG, Rustgi AK, Meyerson M.

Nat Genet. 2009 Nov;41(11):1238-42. doi: 10.1038/ng.465. Epub 2009 Oct 4.

Genome-wide association study in esophageal squamous cell carcinoma.

Bass AJ, Meyerson M.

Gastroenterology. 2009 Nov;137(5):1573-6. doi: 10.1053/j.gastro.2009.09.026. Epub 2009 Sep 27. No abstract available.

Sam Yoon

Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.

Park do J, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, Ilson DH, Goodman KA, Tang LH, Strong VE, Coit DG, Yoon SS.

Ann Surg Oncol. 2014 Apr;21(4):1130-7. doi: 10.1245/s10434-013-3429-0. Epub 2013 Dec 27.

Gastric lymph node contouring atlas: A tool to aid in clinical target volume definition in 3-dimensional treatment planning for gastric cancer.

Wo JY, Yoon SS, Guimaraes AR, Wolfgang J, Mamon HJ, Hong TS.

Pract Radiat Oncol. 2013 Jan-Mar;3(1):e11-9. doi: 10.1016/j.prro.2012.03.007. Epub 2012 May 1.

Prognostic significance of targetable angiogenic and growth factors in patients undergoing resection for gastric and gastroesophageal junction cancers.

Park do J, Yoon C, Thomas N, Ku GY, Janjigian YY, Kelsen DP, Ilson DH, Goodman KA, Tang LH, Strong VE, Coit DG, Yoon SS.

Ann Surg Oncol. 2014 Apr;21(4):1130-7. doi: 10.1245/s10434-013-3429-0. Epub 2013 Dec 27.

Extended lymphadenectomy in gastric cancer is debatable.

Strong VE, Yoon SS.

World J Surg. 2013 Aug;37(8):1773-7. doi: 10.1007/s00268-013-2070-1.

Gastric lymph node contouring atlas: A tool to aid in clinical target volume definition in 3-dimensional treatment planning for gastric cancer.

Wo JY, Yoon SS, Guimaraes AR, Wolfgang J, Mamon HJ, Hong TS.

Pract Radiat Oncol. 2013 Jan-Mar;3(1):e11-9. doi: 10.1016/j.prro.2012.03.007. Epub 2012 May 1.

Staging gastric cancer patients after complete surgical resection: which system should we use?

Yoon SS.

Ann Surg Oncol. 2012 Aug;19(8):2423-5. doi: 10.1245/s10434-012-2405-4. No abstract available.

D1 versus D2 lymphadenectomy for gastric cancer.

Schmidt B, Yoon SS.

J Surg Oncol. 2013 Mar;107(3):259-64. doi: 10.1002/jso.23127. Epub 2012 Apr 18. Review.


An evidence-based review of the surgical treatment of gastric adenocarcinoma.

Maduekwe UN, Yoon SS.

J Gastrointest Surg. 2011 May;15(5):730-41. doi: 10.1007/s11605-011-1477-y. Epub 2011 Mar 12. Review.

How closely should we follow gastric cancer patients following surgical resection?

Yoon SS.

Ann Surg Oncol. 2011 Feb;18(2):311-3. doi: 10.1245/s10434-010-1416-2. No abstract available.

Prophylactic total gastrectomy for individuals with germline CDH1 mutation.

Pandalai PK, Lauwers GY, Chung DC, Patel D, Yoon SS.

Surgery. 2011 Mar;149(3):347-55. doi: 10.1016/j.surg.2010.07.005. Epub 2010 Aug 17.

New metastatic lymph node ratio system reduces stage migration in patients undergoing D1 lymphadenectomy for gastric adenocarcinoma.

Maduekwe UN, Lauwers GY, Fernandez-Del-Castillo C, Berger DL, Ferguson CM, Rattner DW, Yoon SS.

Ann Surg Oncol. 2010 May;17(5):1267-77. doi: 10.1245/s10434-010-0914-6. Epub 2010 Jan 23.

Lymphadenectomy for gastric adenocarcinoma: should west meet east?

Yoon SS, Yang HK.

Oncologist. 2009 Sep;14(9):871-82. doi: 10.1634/theoncologist.2009-0070. Epub 2009 Sep 8.

Case records of the Massachusetts General Hospital. Case 22-2007. A woman with a family history of gastric and breast cancer.

Chung DC, Yoon SS, Lauwers GY, Patel D.

N Engl J Med. 2007 Jul 19;357(3):283-91. No abstract available.

Dr. Sam S. Yoon – Scientific Advisory Board member

front_page_yoonDr. Sam S. Yoon is an Associate Attending in the Division of Gastric and Mixed Tumors at Memorial Sloan-Kettering Cancer Center. He graduated from Harvard University and received his MD from the University of California at San Diego. He completed his residency in general surgery at Massachusetts General Hospital in 2001 and his fellowship in surgical oncology at the Memorial Sloan-Kettering Cancer Center in 2003. He was an Associate Professor of Surgery at Massachusetts General Hospital and Harvard Medical School before joining the staff at Memorial Sloan-Kettering Cancer Center in 2012. Dr. Yoon specializes in treating patients with gastroesophageal cancer and sarcoma. He has been the principal investigator of several clinical trials examining novel treatment strategies and given numerous invited national and international lectures for gastroesophageal cancer and sarcoma. Dr. Yoon’s main research interests are in tumor angiogenesis and the use of targeted biological agents in combination with radiation therapy. He runs an NCI-funded research laboratory which aims to develop translate new research discoveries into the clinic, and he has published over 70 peer-reviewed articles in journals such as the Annals of Surgery, Nature Medicine, and Cancer Cell.
Dr. Yoon serves on the editorial board of several cancer journals including the Oncologist and the Annals of Surgical Oncology. He is a member of several professional and scientific societies including the American College of Surgeons, Society of Clinical Surgery, and the International Gastric Cancer Association, and his awards have included the American Society of Clinical Oncology Young Investigator Award and Society for Surgical Oncology Clinical Investigator Award.
 

Dr. Tony Godfrey – Scientific Advisory Board member

Tony E. Godfrey, PhD, Associate Chair, Surgical Research and Associate Professor of Surgery, Boston University School of Medicine, earned a bachelor’s of science degree in biochemistry from Brunel University in England, followed by a doctorate in molecular biology and biochemistry, also from Brunel. He attended the University of California, San Francisco, for postdoctoral fellowships and managed UCSF’s Genome Analysis Core Facility.

Most recently, Dr. Godfrey was a Research Associate Professor in the Department of Surgery at the University of Rochester Medical Center in Rochester, NY. Prior to this he was an Associate Professor of Pathology at Mt. Sinai School of Medicine in New York, NY.

Dr. Godfrey’s research is focused on cancer genetics and molecular pathology. Research projects use state-of-the-art genetic and genomic approaches to address clinical needs in the areas of cancer diagnosis, prognosis and therapy. Currently the major focus of Dr. Godfrey’s research is on Barrett’s esophagus and esophageal adenocarcinoma; a tumor with rapidly increasing incidence in the United States and other western countries. The Godfrey lab works closely with translational research teams comprised of surgeons, pathologists and oncologists in order to develop new molecular approaches to cancer detection, staging and treatment.

Click Here to read more about Dr. Godfrey’s research and a complete list of his published reports